BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34426077)

  • 21. Histopathological evaluation of resected intraductal papillary mucinous neoplasms reveals distinct patterns of invasion in associated carcinomas.
    Rift CV; Lund EL; Scheie D; Hansen CP; Hasselby JP
    Hum Pathol; 2021 Jul; 113():47-58. PubMed ID: 33915115
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Invasive Pancreatic Ductal Adenocarcinoma versus Intraductal Papillary Mucinous Neoplasm: A National Cancer Database Analysis.
    Ziogas IA; Rodriguez Franco S; Schmoke N; Meguid C; Murphy C; Al-Musawi M; Alexopoulos SP; Schulick RD; Del Chiaro M
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
    Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pancreatic Adenocarcinoma Associated to Intraductal Papillary Mucinous Neoplasia: Histopathological Particularities and Clinical Implications.
    Schlanger D; Popa C; Rusu I; Hajjar NA
    Chirurgia (Bucur); 2022 Jun; 117(4):454-462. PubMed ID: 36049103
    [No Abstract]   [Full Text] [Related]  

  • 25. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
    Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
    Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
    Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
    J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival and prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal adenocarcinoma.
    Woo SM; Ryu JK; Lee SH; Yoo JW; Park JK; Kim YT; Yoon YB
    Pancreas; 2008 Jan; 36(1):50-5. PubMed ID: 18192881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concomitant Intraductal Papillary Mucinous Neoplasm in Pancreatic Ductal Adenocarcinoma Is an Independent Predictive Factor for the Occurrence of New Cancer in the Remnant Pancreas.
    Matsuda R; Miyasaka Y; Ohishi Y; Yamamoto T; Saeki K; Mochidome N; Abe A; Ozono K; Shindo K; Ohtsuka T; Kikutake C; Nakamura M; Oda Y
    Ann Surg; 2020 May; 271(5):941-948. PubMed ID: 30308608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas: an international multicenter cohort study.
    Choi M; Wang SE; Park JS; Kim HS; Choi SH; Lee JH; Chong JU; Nagakawa Y; Wada K; Nakamura Y; Sunagawa H; Dasari BV; Peng CM; Seng LL; Wolters H; Gurbadam U; Park BU; Winslow E; Fishbein T; Hawksworth J; Radkani P; Kang CM
    Int J Surg; 2023 Oct; 109(10):2906-2913. PubMed ID: 37300881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy.
    Kaiser J; Scheifele C; Hinz U; Leonhardt CS; Hank T; Koenig AK; Tjaden C; Hackert T; Bergmann F; Büchler MW; Strobel O
    Eur J Surg Oncol; 2022 Jun; 48(6):1309-1320. PubMed ID: 34920899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm.
    Nakagawa T; Masuda A; Toyama H; Shiomi H; Zen Y; Sofue K; Takenaka M; Kobayashi T; Yagi Y; Yamanaka K; Yoshida M; Arisaka Y; Okabe Y; Kutsumi H; Fukumoto T; Ku Y; Azuma T
    Pancreas; 2017 Apr; 46(4):582-588. PubMed ID: 28099253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm.
    Ikegawa T; Masuda A; Sakai A; Toyama H; Zen Y; Sofue K; Nakagawa T; Shiomi H; Takenaka M; Kobayashi T; Yoshida M; Arisaka Y; Okabe Y; Kutsumi H; Fukumoto T; Azuma T
    Pancreatology; 2018 Jun; 18(4):399-406. PubMed ID: 29685673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intraductal papillary mucinous neoplasms of the pancreas with concurrent pancreatic and periampullary neoplasms.
    Sahora K; Crippa S; Zamboni G; Ferrone C; Warshaw AL; Lillemoe K; Mino-Kenudson M; Falconi M; Fernandez-del Castillo C
    Eur J Surg Oncol; 2016 Feb; 42(2):197-204. PubMed ID: 26687069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive Analysis of Molecular Biologic Characteristics of Pancreatic Ductal Adenocarcinoma Concomitant with Intraductal Papillary Mucinous Neoplasm.
    Tsujimae M; Masuda A; Ikegawa T; Tanaka T; Inoue J; Toyama H; Sofue K; Uemura H; Kohashi S; Inomata N; Nagao K; Masuda S; Abe S; Gonda M; Yamakawa K; Ashina S; Yamada Y; Tanaka S; Nakano R; Sakai A; Kobayashi T; Shiomi H; Kanzawa M; Itoh T; Fukumoto T; Ueda Y; Kodama Y
    Ann Surg Oncol; 2022 Aug; 29(8):4924-4934. PubMed ID: 35606470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between the Risk Factors for Pancreatic Ductal Adenocarcinoma and Those for Malignant Intraductal Papillary Mucinous Neoplasm.
    Kamata K; Takenaka M; Nakai A; Omoto S; Miyata T; Minaga K; Matsuda T; Yamao K; Imai H; Chiba Y; Sakurai T; Watanabe T; Nishida N; Chikugo T; Matsumoto I; Takeyama Y; Kudo M
    Oncology; 2017; 93 Suppl 1():102-106. PubMed ID: 29258117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes.
    Wasif N; Bentrem DJ; Farrell JJ; Ko CY; Hines OJ; Reber HA; Tomlinson JS
    Cancer; 2010 Jul; 116(14):3369-77. PubMed ID: 20564064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas.
    Poultsides GA; Reddy S; Cameron JL; Hruban RH; Pawlik TM; Ahuja N; Jain A; Edil BH; Iacobuzio-Donahue CA; Schulick RD; Wolfgang CL
    Ann Surg; 2010 Mar; 251(3):470-6. PubMed ID: 20142731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncocytic-type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis.
    Marchegiani G; Mino-Kenudson M; Ferrone CR; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
    J Am Coll Surg; 2015 May; 220(5):839-44. PubMed ID: 25840549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determining the role of adjuvant therapy in Invasive Intraductal Papillary Mucinous Neoplasms; a systematic review and meta-analysis.
    Hughes DL; Hughes I; Silva MA
    Eur J Surg Oncol; 2022 Jul; 48(7):1567-1575. PubMed ID: 35144836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive Factors for the Metachronous Development of High-risk Lesions in the Remnant Pancreas After Partial Pancreatectomy for Intraductal Papillary Mucinous Neoplasm.
    Miyasaka Y; Ohtsuka T; Tamura K; Mori Y; Shindo K; Yamada D; Takahata S; Ishigami K; Ito T; Tokunaga S; Oda Y; Mizumoto K; Nakamura M; Tanaka M
    Ann Surg; 2016 Jun; 263(6):1180-7. PubMed ID: 26334637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.